To the nucleolar density and size in apoptotic human leukemic myeloblasts produced in vitro by Trichostatin A.
The present study was designed to provide more information on nucleoli in apoptotic cells,which were represented in the present study by cultured leukemic myeloblasts (Kasumi-1 cells). The apoptotic process in these cells was produced by trichostatin A (TSA) that is a histone deacetylase inhibitor with strong cytostatic effects. The selected TSA concentration added to cultures facilitated to study apoptotic and not-apoptotic cells in one and the same specimen. The nucleolar diameter and density were determined using computer assisted measurement and densitometry in specimens stained for RNA. In comparison with not-apoptotic cells, in apoptotic cells, nucleolar mean diameter did not change significantly and nucleolar RNA density was also not apparently different. On the other hand, the cytoplasmic RNA density in apoptotic cells was markedly reduced. Thus it seemed to be possible that the transcribed RNA remained "frozen"within the nucleolus but its transport to the cytoplasm decreased or stopped. However, the possibility of the RNA degradation in the cytoplasm of apoptotic cells based on the present study cannot be eliminated. At this occasion it should be added that AgNORs reflecting nucleolar biosynthetic and cell proliferation activity in apoptotic cells decreased in number or disappeared. The presented results also indicated that large nucleoli intensely stained for RNA need not be necessarily related to the high nucleolar biosynthetic or cell proliferation activity and may be also present in apoptotic cells responding to the cytostatic treatment.
Smetana
Karel
K
Institute of Hematology and Blood Transfusion, Unemocnice 1, Prague 2, Czech Republic 128 20. karel.smetana@uhkt.cz
Zápotocky
M
M
Starková
J
J
Trka
J
J
D034961:Antigens, Nuclear / Q000032:analysis / Q000648:ultrastructure; D017209:Apoptosis; D045744:Cell Line, Tumor; D002466:Cell Nucleolus / Q000737:chemistry / Q000187:drug effects / Q000648:ultrastructure*; D042381:Granulocyte Precursor Cells / Q000187:drug effects / Q000648:ultrastructure*; D006801:Humans; D006877:Hydroxamic Acids / Q000494:pharmacology; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000473:pathology*; D012313:RNA / Q000032:analysis
D034961:Antigens, Nuclear; D006877:Hydroxamic Acids; C051963:nucleolar organizer region associated proteins; C012589:trichostatin A; D012313:RNA